 |
|
|
Risperdal. Risperdal and Risperdal side effects. Risperdal lawsuits have started. Risperdal prescribed off label, Risperdal side effects, the real Risperdal information.
Risperdal
The bestselling book, How to Get Off Psychiatric Drugs Safely details how to eliminate Risperdal side effects, how to safely taper off Risperdal, what to do if you have already started to taper off Risperdal and are suffering and what you can do if you went off Risperdal too fast and are suffering the Risperdal side effects. This 294 page paperback book is easy to read but technical in the right areas to share with your physician. This successful method of handling these unwanted side effects is used by leading psychiatrists and medical doctors worldwide. In March 2009 the American Medical Association acknowledged psychoactive medications do come with withdrawal side effects and up to 20% of the population will suffer these symptoms while trying to discontinue the medication. How to Get Off Psychiatric Drugs Safely is available exclusively at Amazon.com. Click here to go to the book on Amazon.com. Click Here! to purchase as an eBook $9.95 Warning: You may find this book being sold used for $44.00 on Amazon.com. It is not a collectors item or in short supply. For a change you can purchase something new for less money than something used. The anxiety, insomnia, fatigue, head symptoms that are usually associated with Risperdal withdrawal or the common Risperdal side effects can be a thing of the past.If you are having adverse drug reactions from Risperdal or are thinking of taking Risperdal, there is a probable scientific reason for the adverse drug reactions and a way to predict those Risperdal adverse drug reactions. Click here to read clinical trial. (Opens new browser window) RISPERDAL (RISPERIDONE)RISPERDAL M_TAB (RISPERIDONE) If you are taking Risperdal or thinking of taking Risperdal and you are wondering about side effects or the potential of side effects with using Risperdal, there is something you need to know. There is a way to predict adverse reactions with a very simple test. Dr. Lester M. Crawford, Acting FDA
Commissioner had this to say about this test on TABLETS/ORAL SOLUTION ORALLY DISINTEGRATING TABLETSIf you or your child have been harmed by taking Risperdal, been
prescribed Risperdal off label or had adverse reactions to the medication, you
may wish to file a lawsuit before the statute of limitations runs out. Having a
law firm which understands this medication and most importantly one which has
the resources to see the case through is vital. If you would like for us to send
your information to a law firm handling Risperdal claims, click here and fill
out the short form. The mechanism of action of RISPERDAL (risperidone), as with other drugs used to treat schizophrenia, is unknown. Metabolism Risperidone is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug (e.g., the active moiety) results from the combined concentrations of risperidone plus 9-hydroxyrisperidone. CYP2D6, also called debrisoquin hydrozylase, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythimics, and other drugs, CYP 2D6 is subject to genetic polymorphism (about 6% -8% of Caucasians, and a very low percentage of Asians, have little or no activity and are “poor metabolizers”) and to inhibition by a variety of substrates and some non-substrates, notably quinidine. Extensive CYP 2D6 metabolizers convert risperidone rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of the active moiety, after single and multiple doses, are similar in extensive and poor metabolizers. Risperidone could be subject to two kinds of drug-drug interactions (see PRECAUTIONS-Drug Interactions). First, inhibitors of CYP 2D6 interfere with conversion of risperidone to 9-hydroxyrisperidone. This occurs with quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of risperidone in patients receiving quinidine have not been evaluated, but observations in a modest number (n@70) of poor metabolizers given risperidone do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known enzyme inducers (e.g. phenytoin, rifampin, and phenobarbitital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of risperidone to the enzyme suggest this is unlikely. Back to top of page In a drug interaction study in schizophrenic patients, 11 subjects received risperidone titrated to 6mg/day for 3 weeks, followed by concurrent administration of carbamazepine for an additional 3 weeks. During co-administration, the plasma concentrations of risperidone and its pharmacologically active metabolite, 9-hydroxyrisperidone, were decreased by about 50%. Plasma concentrations of carbanazepine did not appear to be affected. Co-administration of other known enzyme inducers (e.g., phenytoin, rifampin, and Phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment (see PRECAUTIONS – Drug Interactions and DOSAGE ADMINISTRATION – Co-Administration of RISPERDAL with Certain Other Medications).Fluoxetine (20mg QD) and paroxetine (20 mg QD) have been shown to increase the plasma concentration of risperidone 2.5-238 fold and 3-9 fold respectively. Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone. Paroxetine lowered the concentration of 9-hydroxyrisperidone an average of 13% (see PRECAUTIONS – Drug Interactions and DOSAGE AND ADMINISTRATION – Co-Administration of RISPERDAL with Certain Other Medications). Special PopulationsRenal Impairment. Back to top of page In patients with moderate to severe renal disease, clearance of the sume of risperidone and its active metabolite decreased by 60% compared to young healthy subjects. RISPERDAL doses should be reduced in patients with renal disease (see PRECAUTIONS and DOSAGE AND ADMINISTRATION). Hepatic ImpairmentWhile the pharmacokinetics of risperidone in subjects with liver disease were comparable to those in young healthy subjects, the mean free fraction of risperidone in plasma was increased by about 35% because of the diminished concentration of both albumin and or, -acid glycoprotien. Risperdal doses should be reduced in patients with liver disease (see PRECAUTIONS and DOSAGE AND ADMINISTRATION). Race and Gender EffectsNo specific pharmadokintetic study was conducted to investigate race and gender effects, but a population pharmacokinetic analysis did not identify important differences in the disposition of risperidone due to gender (whether corrected for body weight or not) or race. WARNINGS Back to top of pageNeuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipshychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. The management of NMS should include: (1) immediate discontinuation of antipshychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring ; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. If a patient requires antipshychotic drug treatment after recover from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. Back to top of page Tardive DyskinesiaA syndrome of potentially irreversible, involuntary, dyskinesia movements may develop in patients treated with antipshychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipshychotic treatment, which patients are likely to develop the syndrome. Whether antipshychotic drug products differ in their potential to cause Tardive dyskinesia is unknown. The risk of developing Tardive Dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipshychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established cases of Tardive Dyskinesia, although the syndrome my remit, partially or completely, if antipshychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, RISPERDAL (risperidone) should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipshychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipshychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically. If signs and symptoms of Tardive dyskinesia appear in a patient treated on RISPERDAL, drug discontinuation should be considered. However, some patients may require treatment with RISPERDAL despite the presence of the syndrome. Cerebrovascular Adverse Events, Including Stroke, in Elderly Patients With Dementia Cerebrovascular Adverse events (e.g., stroke, transient ischemic attack), including fatalities, were reported in patients (mean age 85 years; range 73-97) in trials of risperidone in elderly patients with dementia-related psychosis. In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse events in patients treated with risperidone compared to patients treated with placebo. RISPERDAL is not approved for the treatment of patients with dementia-related psychosis. Hyperglycemia and Diabetes Mellitus Back to top of pageHyperglycemia, in some cases extreme and associated with detoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including RISPERDAL. Assessment of the relationship between atypical antipshychotic use and glucose abnormalities is complicated by the possibility of an increased background fisk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipshychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug. PRECAUTIONS Back to top of page General Orthostatic HypotensionRISPERDAL (risperidone) may induce orthostatic hypotension associated with dizziness, tychycardia, and in some patients, syncope, especially during the initial dose-titration period, probably reflection its alpha-adrenergic antagonistic properties. Syncope was reported in 0.2% (6/2607) of RISPERDAL treated patients in Phase 2 and 3 studies. The risk of orthostatic hypotension and syncope may be minimized by limiting the initial dose to 2 mg total (either QD or 1mg BID) in normal adults and 0.5 mg BID in the elderly and patients with renal or hepatic impairment (see DOSAGE AND ADMINISTRATION). Monitoring of orthostatic vital signs should be considered in patients for whom this is of concern. A dose reduction should be considered if hypotension occurs. RISPERDAL should be used with particular caution in patients with known cardiovascular disease (history of myocardial infraction or ischemia, heart failure, or condition abnormalities), cerebrovascular disease, and conditions, which would predispose patients to hypotension, e.g., dehydration and hypovolemia. Clinically significant hypotension has been observed with concomitant use of RISPERDAL and antihypertensive medication. Seizures Back to top of pageDuring premarketing testing, seizures occurred in 0.3% (9/2607 of RISPERDAL treated patients, two in association with hyponatremia. RISPERDAL should be used cautiously in patients with a history of seizures. DysphagiaEsophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer’s dementia. RISPERDAL and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. Hyperprolactinemia Back to top of pageAs with other drugs that antagonize dopamine D2 receptors, resperiodone elevates prolactin levels and the elevation persists during chronic administration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds, the clinical significance of elevated serum prolactin levels is unknown for most patients. As is common with compounds which increase prolactin release, an increase in pituitary gland, Mammary glend, and pancreatic islet cell hyperplasia and /or neoplasia was observed in the risperidone carcinogenicity studies conducted in mice and rats (see PRECAUTIONS – Carcinogenesis, Mutagenesis, Impairment of Fertility). However, neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time. Potential for Cognative and Motor ImpairmentSomnolence was commonly reported adverse event associated with RISPERDAL treatment, especially when ascertained by direct questioning of patients. This adverse event is dose-related, and in a study utilizing a checklist to detect adverse events, 41% of the high-dose patients (RISPERDAL 16 mg/day) reported somnolence compared to 16% of placebo patients. Direct questioning is more sensitive for detecting adverse events than spontaneous reporting, by which 8% of RISPERDAL 16mg/day patients and 1% of placebo patients reported somnolence as an adverse event. Since RISPERDAL has the potential to impair judgment, thinking or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that RISPERDAL therapy does not affect them adversely. Priapism Back to top of pageRare cases of priapism have been reported. While the relationship of the events to RISPERDAL use has not been established, other drugs with alpha-adrenergic blocking effects have been reported to induce priapism, and it is possible that RISPERDAL may share this capacity. Severe priapism may require surgical intervention. Thrombotic Thrombocytopenic Purpura (TTP) A single case of TTP was reported in a 28-year-old female patient receiving RISPERDAL in a large, open premarketing experience (approximately 1300 patients). She experienced jaundice, fever, and bruising, but eventually recovered after receiving plasmapheresis. The relationship to RISPERDAL therapy is unknown. Antiemetic Effect Risperidone has an antiemetic effect in animals; this effect may also occur in humans, and may mask signs and symptoms of overdosage with certain drugs or of conditions such as intestinal obstruction, Reye’s syndrome, and brain tumor. Body Temperature Regulation Back to top of pageDisruption of body temperature regulation has been attributed to antipsychotic agents. Both hyperthermia and hypothermia have been reported in association with oral RISPERDAL us. Caution is advised when prescribing for pactients who will be exposed to temperature extremes. SuicideThe possibility of suicide attempt is inherent in schizophrenia, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for RISPERDAL should be written for the smallest quantity of tablets, consistent with good patient management, in order to reduce the risk of overdose. Use in Patients with Concomitant IllnessClinical experience with RISPERDAL in patients with certain concomitant systemic illnesses is limited. Caution is advisable in using RISPERDAL in patients with disease of conditions that could affect metabolism or hemodynamic responses. RISPERDAL has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from clinical studies during the product’s premarket testing. Increased plasma concentrations of risperidone and 9-hydroxyrisperidone occur in patients with severe renal impairment (creatinine clearance <30 mL/min/1.73 m2), and an increase in the free fraction of risperidone is seen in patients with severe hepatic impairment. A lower starting dose should be used in such patients (seeDOSAGE AND ADMINISTRATION). Information for Patients Back to top of pagePhysicians are advised to discuss the following issues with patients for whom they prescribe RISPERDAL. Orthostatic HypotensionPatients should be advised of the risk of orthostatic hypotension, especially during the period of initial dose titration. Interference with Cognitive and Motor PerformanceSince RISPERDAL has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that RISPERDAL therapy does not affect them adversely. PregnancyPatients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy. Nursing Back to top of pagePatients should be advised not to breast-feed an infant if they are taking RISPERDAL Concomitant MedicationPatients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactions. AlcoholPatients should be advised to avoid alcohol while taking RISPERDAL. PhenylketonuricsPhenylalanine is a component of aspartame. Each 2 mg RISPERDAL M-TAB Orally Disintegrating Tablet contains 0.56mg phenylalanine; each 1mgRISPERDAL M_TAB Orally Disintegrating Tablet contains 0.28 mg phenylalanine; and each 0.5 mg RISPERDAL M_TAB Orally Disintegrating Tablet contains 0.14 mg phenylalanine. Laboratory Tests No specific laboratory tests are recommended Drug Interactions Back to top of pageThe interactions of RISPERDAL and other drugs have not been systematically evaluated. Given the primary CNS effect of risperidone, caution should be used when RISPERDAL is taken in combination with other centrally acting drugs and alcohol. Because of its potential for inducing hypotension. RISPERDAL may enhance the hypotensive effects of other therapeutic agents with this potential. RISPERDAL may antagonize the effects of levodopa and dopamine agonists. Amtripyline does not affect the pharmacokinetics of risperidone of the active antipsychotic fraction. Cimetidine and ranitidine increased the bioavaiability of risperidone, but only marginally increased the plasma concentration of the active antipsychotic fraction. Chronic administration of clozapine with risperidone may decrease the clearance of risperidone. Carbamazepine and Other Enzyme InducersIn a drug interaction study in scizophrenic patients, 11 subjects received risperidone titrated to 6 mg/day for 3 weeks, followed by concurrent administration of carbamazepine for an additional 3 weeks. During co-administration, the plasma concentrations of risperidone and its pharmacologically active metabolite, 9-hydroxyrisperidone, were decreased by about 50%. Plasma concentrations of carbamazepine did not appear to be affected. The does of risperidone may need to be titrated accordingly for patients receiving carbamazepine, particularly during initiation or discontinuation of carbamazepine therapy. Co-administration of other known enzyme inducers) e.g., phenytoin, rifampin, and Phenobarbital) with risperidone may cause similar decreases in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone, which could lead to decreased efficacy of risperidone treatment. Fluoxetine and Paroxetine Back to top of pageFluoxetine (20 mg QD) and paroxetine (20 mg QD) have been shown to increase the plasma concentration of risperidone 2.5-2.8 fold and 3-9 fold respectively. Fluoxetine did not affect the plasma concentration of 9-hydroxyrisperidone. Paroxetine lowered the concentration of 9-hydroxyrisperidone an average of 13%. When either concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dosing of RISPERDAL. The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and 9-hydroxyrisperidone have not been studied LithiumRepeated oral doses of risperidone (3 mg BID) did not affect the exposure (AUD) or peak plasma concentrations (C max) of lithium (n@13). ValproateRepeated oral doses of risperidone (4 mg QD) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000mg/day in three divided doses) compared to placebo (n+12). However, there was a 20% increase in valproate peak plasma concentration (C max) after concomitant administration of risperidone. Digoxin Back to top of pageRISPERDAL (0.25 mg BID) did not show a clinically relevant effect on the pharmacokinetics of digoxin. Drugs That Inhibit CYP 2D6 and Other CYP IsozymesRisperidone is metabolized to 9-hydroxyrisperidoneby CYP 2D6, an enzyme that is polymorphic in the population and that can be inhibited by a variety of psychotropic and other drugs (see CLINICAL PHARMACOLOGY). Drug interactions that reduce the metabolism of risperidone to 9-hydroxyrisperidone would increase the plasma concentrations of risperidone and lower the concentrations of 9-hydroxyrisperidone. Analysis of clinical studies involving a modest number of poor metabolizers (n@70) does not suggest that poor and extensive metabolizers have different rates of adverse effects. No comparison of effectiveness in the two groups has been made. In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1. 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism. There were no significant interactions between risperidone and erythromycin (see CLINICAL PHARMACOLOGY). Drugs Metabolized by CYP 2D6 Back to top of pageIn vitro studies indicate that risperidone is a relatively week inhibitor of CYP 2D6. Therefore, RISPERDAL is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway. In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6. Carcinogenesis, Mutagenesis, Impairment of Fertility CarcinogenesisCarcinogenicity studies were conducted in Swiss albino mice and Wistar rats. Risperidone was administered in the diet at doses of 0.63, 2.5, and 10 mg/kg for 18 months to mice and for 25 months to rats. These doses are equivalent to 2.4, 9.4, and37.5 times the maximum recommended human dose (MRHD) (16 mg/day) on a mg/kg basis or 0.2, 0.75, and 3times the MRHD (mice) or 0.4, 1.5, and 6 times the MRHD (rats) on a mg/m2 basis. A maximum tolerated dose was not achieved in male mice. There were statistically significant increases in pituitary gland adenomas, endocrine pancreas adenomas, and mammary gland adenocarcinomas. The following table summarizes the multiples of the human dose on the mg/m2 (mg/mk) basis at which these tumors occurred. Tumor Type Species Sex Multiples of Maximum Human DoseIn mg/m2 (mg/kg) Lowest Highest Effect No-Effect Level Level Pituitary adenomas mouse female 0.75 (9.4) 0.2 (2.4) Endocrine pancreas rat male 1.5 (9.4) 0.4 (2.4) Adenomas Mammary gland mouse female 0.2 (2.4 none Adenocarcinomas Rat female 0.4 (2.4) none Rat male 6.0 (37.5) 1.5 (9.4) Mammary gland rat male 1.5 (9.4) 0.4 (2.4) Neoplasm, Total Back to top of page Antipsychotic drugs have been shown to chronically elevate prolactin levels in rodents. Serum prolactin levels were not measured during the risperidone carcinogenicity studies; however, measurements during subchronic toxicity studies showed that risperidone elevated serum prolactin levels 5-6 fold in mice and rats at the same doses used in the carcinogenicity studies. An increase in mammary, pituitary, and endocrine pancreas neoplasm has been found in rodents after chronic administration of other antipsychotic drugs and is considered to be prolactin-mediated. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown (see PRECAUTIONS, General – Hyperprolactinemia). MutagenesisNo evidence of mutagenic potential for risperidone was found in the Ames reverse mutation test, mouse lymphoma assay, in vitro rat hepatocyte DNA-repair assay, in vivo micronucleus test in mice, the sex-linked recessive lethal test in Drosophila, or the chromosomal aberration test in human lymphocytes or Chinese hamster cells. Impairment of FertilityRisperidone (0.16 to 5 mg/kg) was shown to impair mating, but not fertility, in Wistar rats in three reproductive studies (two Segment 1 and a muligenerational study) at doses 0.1 to 3 times the maximum recommended human dose (MRHD) on a mg/m2 basis. The effect appeared to be in females, since impaired mating behavior was not noted in the Segment 1 study in which sperm motility and concentration were decreased at doses 0.6 to 10 times the MRHD on a mg/m2 basis. Dose-related decreases were also noted in serum testosterone at the same doses. Serum testosterone and sperm parameters partially recovered, but remained decreased after treatment was discontinued. No no-effect doses were noted in either rat or dog. Pregnancy Back to top of pagePregnancy Category C The teratogenic potential of risperidone was studied in three Segment 11 studies in Sprague-Dawley and Wistar rats (0.63-10mg/kg or 0.4 to 6 times the maximum recommended human dose [MRHD] on a mg/m2 basis) and in one Segment 11 study in New Zealand rabbits (0.31-5 mg/kg or 0.4 to 6 times the MRHD on a mg/m2 basis). The incidence of malformations was not increased compared to control in offspring of rats or rabbits given 0.4 to 6 times the MRHD on a mg/m2 basis. In three reproductive studies in rats (two Segment 111 and a multigenerational study), there was an increase in pup deaths during the first 4 days of lactation at doses of 0.16-5 mg/kg or 0.1 to 3 times the MRHD on a mg/m2 basis. It is not known whether these deaths were due to a direct effect on the fetuses or pups or to effects on the dams. There was no no-effect dose for increased rat pup mortality. In one Segment 111 study, there was an increase in stillborn rat pups at a dose of 2.5 mg/kg or 1.5 times the MRHD on a mg/m2 basis. In a cross-fostering study in Wistar rats, toxic effects on the fetus or pups, as evidenced by a decrease in the number of live pups and an increase in the number of dead pups at birth (Day 0), and a decrease in birth weight in pups of drug-treated dams were observed. In addition, there was an increase in deaths by Day 1 among pups of drug-treated dams, regardless of whether or not the pups were cross-fostered. Risperidone also appeared to impair maternal behavior in that pup body weight gain and survival (from Day 1 to 4 of lactation) were reduced in pups born to control by reared by drug-treated dams. These effects were all noted at the one dose of risperidone tested, i.e., 5 mg/kg or 3 times the MRHD on a mg/m2 basis. Placental transfer of risperidone occurs in rat pups. There are no adequate and well-controlled studies in pregnant women. However, there was one report of a case of agenesis of the corpus callosum in an infant exposed to risperidone in utero. The causal relationship to RISPERDAL therapy is unknown. RISPERDAL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Labor and Delivery Back to top of pageThe effect of RISPERDAL on labor and delivery in humans is unknown. Nursing MothersIn animal studies, risperidone and 9-hydroxyrisperidone are excreted in milk. Risperidone and 9-hydroxyrisperidone are also excreted in human breast milk. Therefore, women receiving risperidone should not breast-feed. Pediatric UseSafety and effectiveness in children have not been established. Geriatric Use Back to top of pageClinical studies of RISPERDAL did not include sufficient numbers of patients aged 65 and over to determine whether or not thy respond differently than younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, a lower starting dose is recommended for an elderly patient, reflecting a decreased pharmacokinetic clearance in the elderly, as well as a greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTATION). While elderly patients exhibit a greater tendency to orthostatic hypotension, its risk in the elderly may be minimized by limiting the initial dose to 0.5 mg BID followed by careful titration (see PRECAUTIONS). Monitoring of orthostatic vital signs should be considered in patients for whom this is of concern. This drug is substantially excreted by the kidneys, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection ,a and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION). ADVERSE REACTIONSThe following findings are based on the short-term, placebo-controlled, North American, premarketing trial for schizophrenia and acute bipolar mania, In patients with Bipolar 1 Disorder, treatment-emergent adverse events are presented separately for risperidone as monotherapy and as adjunctive therapy to mood stabilizers. Certain portions of the discussion below relating to objective or numeric safety parameters, namely dose-dependent adverse events, vital sign changes, weight gain, laboratory changes, and ECG changes are derived from studies in patients with schizophrenia. However, this information is also generally applicable to bipolar mania. Associated With Discontinuation of Treatment Back to top of pageSchizophrenia Approximately 9% (244/2607 of RISPERDAL (risperidone)-treated patients in Phase 2 and 3 studies discontinued treatment due to an adverse event, compared with about 7% on placebo and 10% on active control drugs. The more common events (≥0.3%) associated with discontinuation and considered to be possibly or probably drug-related included: Adverse Event RISPERDAL Placebo Extrapyramidal symptoms 2.1% 0% Dizziness 0.7% 0% Hyperkinesia 0.6% 0% Somonlence 0.5% 0% Nausea 0.3% 0%
Suicide attempt was associated with discontinuation in 1.2% of RISPERDAL- treated patients compared to 0.6% of placebo patients, but, given the almost 40-fold greater exposure time in RIPERDAL compared to placebo patients, it is unlikely that suicide attempt is a RISPERDAL-related adverse event (see PRECAUTIONS). Discontinuation for extrapyramidal symptoms was 0% in placebo patients, but 3.8% in active-control patients in the Phase 2 and 2 trials. Bipolar Mania In the US placebo-controlled trail with risperidone as monotherapy, approximately 8% (10/134) of RISPERDAL-treated patients discontinued treatment due to an adverse event, compared with approximately 6% (7/125) of placebo-treated patients. The adverse events associated with discontinuation and considered to be possibly, probably, or very likely drug-related included paroniria, somnolence, dizziness, extrapyramidal disorder and muscle contractions involuntary. Each of these events occurred in one RISPERDAL-treated patient (0.7%) and in no placebo-treated patients (0%) In US placebo-controlled trial with risperidone as adjunctive therapy to mood stabilizers, there was no overall difference in the incidence of discontinuation due to adverse events (4% for RISPERDAL vs. 4% for placebo). Incidence in Controlled Trials Commonly Observed Adverse Events in Controlled Clinical Trials Schizophrenia Back to top of page In tow 6-to 8-week placebo-controlled trials, spontaneously-reproted, treatment-emergent adverse events with an incidence of 5% or greater in at least one of the RISPERDAL groups and at least twice that of placebo were anxiety, somnolence, extra-pyramidal symptoms, dizziness, constipation, nausea, dyspepsia, rhinitis, rash, and tachycardia. Adverse events were also elicited in one of these two trails. (i.e., in the fixed-dose trial comparing RISPERDAL at doses of 2,6,10, and 16 mg/day with placebo) utilizing a checklist for detecting adverse events, a method that is more sensitive than spontaneous reporting. By this method, the following additional common and drug-related adverse events occurred at an incidence of at least 5% and twice the rate of placebo; increased dream activity, increased duration of sleep, accommodation disturbances, reduced salivation, micturition disturbances, diarrhea, weight gain, menorrhagia, diminished sexual desire, erectile dysfunction, ejaculatory dysfunction, and orgastic dysfunction. Bipolar Mania Back to top of page In the US placebo-controlled trial with risperidone as monotherapy, the most commonly observed adverse events associated with the use of RISPERDAL (incidence of 5% or greater and at least twice that of placebo) were somnolence, dystonia, akathisia, dyspepsia, nausea, parkinsonism, vision abnormal, and saliva increased. In the US placebo-controlled trial with risperidone as adjunctive therapy to mood stabilizers, the most commonly observed adverse events associated with the use of RISPERDAL were somnolence, dizziness, parkinsonism, saliva increased, akathisia, abdominal pain, and urinary incontinence. Adverse Events Occurring at an Incidence of 1% or More Among RISPERDAL - Treated Patients - Schizophrenia The table that follows enumerates adverse events that occurred at an incidence of 1% or more, and were more frequent among RISPERDAL – treated patients treated at doses of ≤10 mg/day than among placebo-treated patients in the pooled results of two 6- to 8- week controlled trials. Patients received RISPERDAL doses of 2,6,10, or 16 mg/day in the dose comparison trial, or up to a maximum dose of 10mg/day in the titration study. This table shows the percentage of patients in each dose group (≤10 mg/day or 16 mg/day) who spontaneously reported at least one episode of an event at some time during their treatment. Patients given doses of 2,6, or 10 mg did not differ materially in these rates, Reported adverse events were classified using the World Health Organization preferred terms. Back to top of page The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in this clinical trial. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the side effect incidence rate in the population studied. Table 1. Incidence of Treatment-Emergent Adverse EventsIn 6- to 8- Week Controlled Clinical Trials (1) Body System RISPERDALPreferred Term ≤10 mg/day 16 mg/day Placebo (N=324) (N=77) (N=142) ______________________________________________________________________ Psychiatric 26% 23% 19% Insomnia 22% 26% 20% Agitation 22% 26% 20% Anxiety 12% 20% 20% Somnolence 3% 8% 1% Aggressive reaction 1% 3% 1% Central &peripheral nervous systemExtapyramidal Symptoms 17% 34% 16% Headache 14% 12% 12% Dizziness 4% 7% 1% GastrointestinalConstipation 7% 13% 3% Nausea 6% 4% 3% Dyspepsia 5% 10% 4% Vomiting 5% 7% 4% Abdominal pain 4% 1% 0% Saliva increased 2% 0% 1% Toothache 2% 0% 0% Respiratory system Back to top of pageRhinitis 10% 8% 4% Coughing 3% 3% 1% Sinusitis 2% 1% 1% Pharyngitis 2% 3% 0% Dyspnea 1% 0% 0% Body as a whole – generalBack pain 2% 0% 1% Chest pain 2% 3% 1% Fever 2% 3% 0% Dermatological Back to top of pageRash 2% 5% 1% Dry Skin 2% 4% 0% Seborrhea 1% 0% 0% InfectionsUpper respiratory 3% 3% 1% VisualAbnormal vision 2% 1% 1% Musculo-SkeletalArthralgia 2% 3% 0% Cardiovascular Tachycardia 3% 5% 0% (1) Events reported by at least 1% of patients treated with RISPERDAL ≤10 mg/day are included, and are rounded to the nearest %. Comparative rates for RISPERDAL 16 mg/day and placebo are provided as well. Events for which the RISPERDAL incidence (in both dose groups) was equal to or less than placebo are not listed in the table, but included the following: nervousness, injury, and fugal infection. (2) Includes tremor, dystonia, hypokinesia, hypertonia, hyperkinesias, oculogyriccrisis, ataxia, abnormal gait, involuntary muscle contractions, hyporeglexia, akathisia, and extrapyramidal disorders. Although the incidence of ‘extrapyramidal symptoms’ does not appear to differ for the ’10 mg/day’ group and placebo, the data for individual dose groups in fixed dose trials do suggest a dose/response relationship (see ADVERSE REACTIONS- Dose Dependency of Adverse Events). Back to top of page Adverse Events Occurring at an Incidence of 2% or More Among RISPERDAL – Treated Patients - Bipolar Mania Tables 2 and 3 display adverse events that occurred at an incidence of 2% or more, and were more frequent among patients treated with flexible doses of RISPERDAL (1-6 mg daily as monotherapy and as adjunctive therapy to mood stabilizers, respectively_ than among patients treated with placebo. Reported adverse events were classified using the World Health Organization preferred terms. Table 2. Incidence of Treatment-Emergent Adverse Events In a 3-Week, Placebo-Controlled Trial – Monotherapy in Bipolar Mania (1) Body System/ RISPERDAL PlaceboPreferred Term (N=134) (N=125)__________ Central & peripheral nervous systemDystonia 18% 6% Akathisia 16% 6% Dizziness 11% 9% Parkinsonism 6% 3% Hypoaesthesia 2% 1% PsychiatricSomnolence 28% 7% Agitation 8% 6% Manic Reaction 8% 6% Anxiety 4% 2% Concentration impaired 2% 1% Gastrointestinal systemDyspepsia 11% 6% Nausea 11% 2% Saliva increased 5% 1% Mounth dry 3% 2% Body as a whole – generalPain 5% 3% Fatigue 4% 2% Injury 2% 0% Respitory systemSinusitis 4% 1% Rhinitis 3% 2% Coughing 2% 2% Skin appendageAcne 2% 0% Pruritus 2% 1% Musculo-SkeletalMyalgia 5% 2% Skeletal pain 2% 1% Metabolic and nutritionalWeight increase 2% 0% Vision DisordersVision abnormal 6% 2% Cardiovascular, generalHypertension 3% 1% Hypotension 2% 0% Heart rate and rhythmTachycardia 3% 2%(1) Events reported by at least 2% of patients treated with RISPERDAL are included and are rounded to the nearest %. Events reported by at least 2% of patients treated with RISPERDAL that were less than the incidence reported by patients treated with placebo are not listed in the table, but included the following; headache, tremor, insomnia, constipation, back pain, upper respiratory tract infection, pharyngitis, and arthralgia. Back to top of page Table 3. Incidence of Treatment-Emergent Adverse EventsIn a 3-Week, Placebo-Controlled Trial – adjunctive Therapy In Bipolar Mania (1) RISPERDAL PLACEBO Body System/ + Mood Stabilizer + Mood Stabilizer Preferred Term (N=52) (N+51)__________ Gastrointestinal system Saliva increased 10% 0% Diarrhea 8% 4% Abdominal pain 6% 0% Constipation 6% 4% Mount dry 6% 4% Tooth ache 4% 0% Tooth disorder 4% 0% Central & peripheral nervous system Dizziness 14% 2% Parkinsonism 14% 4% Akathisia 8% 0% Dystonia 6% 4% Psychiatric Somnolence 25% 12% Anxiety 6% 4% Confusion 4% 0% Respiratory system Rhinitis 8% 4% Pharyngitis 6% 4% Coughing 4% 0% Body as a whole – general Asthenia 4% 2% Urinary System Urinary incontinence 6% 2% Heart rate and rhythm Tachycardia 4% 2% Metabolic and nutritional Weight increase 4% 2% Skin and appendages Rash 4% 2%___________ (1) Events reported by at least 2% of patients treated with RISPERDAL are included and are rounded to the nearest %. Events reported by at least 2% of patients treated with RISPERDAL that were less than the incidence reported by patients treated with placebo are not listed in the table, but included the following: dyspepsia, nausea, vomiting, headache, tremor, insomnia, chest pain, fatigue pain, skeletal pain, hypertension, and vision abnormal. Dose Dependency of Adverse Events Back to top of page Extrapyramidal Symptoms Data from two fixed-dose trials provided evidence of dose-relatedness for extrapyramidal symptoms associated with risperidone treatment. Two methods were used to measure extrapyramidal symptoms (EPS) in an 8-week trial comparing 4 fixed doses of risperidone (2, 6,10, and 16 mg/day), in parkinsonism score (mean change from baseline) from the Extrapyramidal Symptom Rating Scale, and (2) incidence of spontaneous complaints of EPS. Dose Groups Placebo Ris 2 Ris 6 Ris 10 Ris 16 Parkinsonism 1.2 0.9 1.8 2.4 2.6 EPS Incidence 13% 13% 16% 20% 31% Simialr methods were used to measure extrapyramidal symptoms (EPS) in an 8-week trial comparing 5 fixed doses of risperidone (1, 4, 8, 12, and 16 mg/day): Dose Groups Ris 1 Ris 4 Ris 8 Ris 12 Ris 16 Parkinsonism .06 1.7 2.4 2.9 4.1 EPS Incidence 7% 12% 18% 18% 21% Other Adverse Events Back to top of page Adverse event data elicited by a checklist for side effect from a large study comparing 5 fixed doses of RISPERDAL (1, 4, 8, 12, 16 mg/day) were explored for dose-relatedness of adverse events. A Cochran-Armitage Test for trend in these data revealed a positive trend (p<0.05) for the following adverse events: sleepiness, increased duration of sleep, accommodation disturbances, orthostatic dizziness, palpitations, weight gain, erectile dysfunction, ejaculatory dysfunction, orgastic dysfunction, asthenia/lassitude/increased fatigability, and increased pigmentation. Vital Sign Changes RISPERDAL is associated with orthostatic hypotension and tachycardia (see PRECAUTIONS). Weight Changes The proportions of RISPERDAL and placebo-treated patients meeting a weight gain criterion of ≥7% of body weight were compared in a pool of 6- to 8- week placebo-controlled trials, revealing a statistically significantly greater incidence of weight gain for RISPERDAL (18%) compared to placebo (9%). Laboratory Changes Back to top of page A between-group comparison for 6- to 8-week placebo-controlled trials revealed no statistically significant RISPERDAL/placebo differences in the proportions of patients experiencing potentially important changes in routine serum chemistry, hematology, or urinalysis parameters. Simiarly, there were no RISPERDAL/placebo differences in the incidence of discontinuations for chages in serum chemistry, hematology, or urinalysis. However, RISPERDAL administration was associated with increases in serum prolactin (see PRECAUTIONS). ECG Changes Between-group comparisons for pooled placebo-controlled trials revealed no statistically significant differences between risperidone and placebo in mean changes from baseline in ECG parameters, including QT, QTc an PR intervals, and heart rate. When all RISPERDAL doses were pooled from randomized controlled trials in several indications, there was a mean increase in heart rate of 1 beat per minute compared to no change for placebo patients. In short-term schizophrenia trials, higher doses of risperidone (8-16 mg/day) were associated with a higher mean increase in heart rate compared to placebo (4-6 beats per minute). Other Events Observed During the Premarketing Evaluation of RISPERDAL During its premarketing assessment, multiple doses of RISPERDAL were administered to 2607 patients in Phase 2 and 3 studies. The conditions and duration of exposure to RISPERDAL varied greatly, and included (in overlapping categories) open-label and double-blind studies, uncontrolled and controlled studies, inpatient and outpatient studies, fixed-dose and titration studies, and short-term or longer-term exposure. In most studies, untoward events associated with this exposure were obtained by spontaneous report and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event categories. In two large studies, adverse events were also elicited utilizing the UKU (direct questioning) side effect rating scale, and these events were not further categorized using standard terminology. (Note: these events are marked with an asterisk in the listings that follow.) In the listings that follow, spontaneously reported adverse events were classified using World Health Organization (WHO) preferred terms. The frequencies presented, therefore, represent the proportion of the 2607 patients exposed to multiple doses of RISPERDAL who experienced an event of the type cited on at least one occasion while receiving RISPERDAL. All reported events are included, except those already listed in Table 1, those events for which a drug cause was remote, and those event terms which were so general as to be uninformative. It is important to emphasize that, although the events reported occurred during treatment with RISPERDAL, they were not necessarily caused by it. Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring in at least 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing); infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients. Psychiatric Disorders Back to top of page Frequent: increased dream activity*, diminished sexual desire*, nervousness. Infrequent: impaired concentration, depression. Apathy, catatonic reaction, euphoria, increased libido, amnesia. Rare: emotional lability, nightmares, delirium, withdrawal syndrome, yawning. Central and Peripheral Nervous System Disorders Frequent: increased sleep duration*. Infrequent: dysarthria, vertigo, stupor, paraesthesia, confusion. Rare: aphasia, cholinergic syndrome, hypoesthesia, tongue paralysis, leg cramps, torticollis, hypotonia, coma, migraine, hyperreflexia, choreoathetosis. Gastrointestinal Disorders Frequent: anorexia, reduced salivation*. Infrequent: flatulence, diarrhea, increased appetite, stomatitis, melena, dysphagia, gerorrhoids, gastritis. Rare: fecal incontinence, eructation, gastroesophageal reflux. Gastroentertits, esophagitis, tongue discoloration, cholelithiasis, tongue edema, diverticulitis, gingivitis, discolored feces, GI hemorrhage, hematemesis. Body as a Whole/General Disorders Back to top of page Frequent: fatigue. Infrequent: edema, rigors, malaise, influenza-like symptoms. Rare: pallor, enlarged abdomen, allergic reaction, ascites, sarcoidosis, flushing. Respirator System Disorders Infrequent: hyperventilation, bronchospasm, pneumonia, stridor. Rare: asthma, increased sputum, aspiration. Skin and Appendage Disorders Frequent: increased pigmentation*, photosensitivity*,. Infrequent: Increased sweatin, acne, decreased sweating, alopecia, hyperkeratosis, pruritus, skin exfoliation. Rare: bullous eruption, skin sulceration, aggravated psoriasis, furunculosis, veruca, dermatitis lichenoid, hypertrichosis, geital pruritus, urticaria. Cardiovascular Disorders Infrequent: palpitation, hypertension, hypotension, AV block, myocardial infarction. Rare: ventricular tachycardia, angina pectoris, premature atrial contractions, T wave inversions, bentricular extasystoles, ST depression, myocarditis. Vision Disorders Back to top of page Infrequent: abnormal accommodation, xerophthalmia. Rare: diplopia, eye pain, blepharitis, photopsia, photophobia, abnormal lacrimation. Metabolic and Nutritional Disorders Infrequent: hyponatremia, weight increase, creatinine phosphokinase increse, thirst, weight decrease, diabetes mellitus. Rare: decreased serum iron, cachexia, dehydration, hypokalemia, hypoproteinemia, hyperphosphatemia, hypertriglyceridemia, hyperuicemia, hypoglycemia. Urinary System Disorders Frequent: polyuria/polydipsia*. Infrequent: urinary incontinence, hematuria, dysuria. Rare: urinary retention, cystitis, renal insufficiency. Musculo-Skeletal System Disorders Back to top of page Infrequent: Myalgia. Rare: arthrosis, synostosis, bursitis, arthritis, skeletal pain. Reproductive Disorders, Female Frequent: menorrhagia*, orgastic dysfunction*, dry vagina*. Infrequent: nonpuerperal lactation, amenorrhea, female breast pain, leukorrhea, mastitis, dysmenorrhea, female perineal pain. Intermenstrual bleeding, vaginal hemorrhage. Liver and Biliary System Disorders Infrequent: increased SGOT, increased SGPT. Rare: hepatic failure, cholestatic hepatitis, cholecystitis, cholelithiasis, hepatitis, hepatocullular damage. Platelet, Bleeding, and Clotting Disorders Back to top of page Infrequent: epistaxis, purpura. Rare: hemorrhage, superficial phlebitis, thrombophebitis, thrombocytopenia. Hearing and Vesitbular Disorders Rare: tinnitus, hyperacusis, decreased hearing. Red Blood Cell Disorders Infrequent: anemia, hypochromic anemia. Rare: normocytic anemia. Reproductive Disorders, Male Frequent: erectile dysfunction*. Infrequent: ejaculation failure. White Cell and Resistance Disorders Rare: leukocytosis, lymphadenopathy, leucopenia, Pelger-Huet anomaly. Endocrine Disorders Rare: gynecomastia, male breast pain, antiduretic hormone disorder. Special Senses Rare: bitter taste. *Incidence based on elicited reports. Postintroduction Reports Back to top of page Adverse events reported since market introduction, which were temporally (but not necessarily causally) related to RISPERDAL therapy, include the following: anaphylactic reaction, angioedema, apnea, atrial fibrillation, cerebrovascular disorder, including cerebrovascular accident, hyperglycemia, diabetes mellitus aggravated, including diabetic ketoacidosis, intestinal obstruction, jaundice, mania, pancreatitis, Parkinson’s disease aggravated, pulmonary embolism. There have been rare reports of sudden death and/or cardiopulmonary arrest in patients receiving RISPERDAL. A causal relationship with RISPERDAL has not been established. It is important to note that sudden and unexpected death may occur in psychotic patients whether they remain untreated or whether they are treated with other antipsychotic drugs. DRUG ABUSE AND DEPENDENCE Controlled Substance Class RISPERDAL (risperidone) is not a controlled substance. Physical and Psychological Dependence RISPERDAL has not been systematically studied in animals or humans for its potential for abuse, tolerance, or physical dependence. While the clinical trials did not reveal any tendency for any drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of RISPERDAL misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior).
|
If you
are struggling with Risperdal side effects, want to taper off Risperdal, have
already started to reduce Risperdal or quit Risperdal cold turkey, there is help
and there is a solution.